


NEWS RELEASE**Teijin and BioVaram Form Strategic Alliance to Expand Usage Regenerative Medicine Products and Implantable Medical Devices in Japan and India**

Tokyo, November 13, 2025 --- [Teijin Limited](#) and [BioVaram](#), the brand name of the **UR Advanced Therapeutics Pvt Ltd. (URAT)**, announced today that they have signed a business alliance agreement to explore opportunities for expanding usage of Teijin Group's implantable medical devices and regenerative medicine products in India, as well as introducing BioVaram's product portfolio into the Japanese market.

The two companies share a vision to address unmet medical needs in Japan—one of the world's most advanced healthcare markets—and India, where healthcare innovation is accelerating. This alliance aims to leverage each company's strengths to deliver cutting-edge solutions across both nations.

Under the agreement, Teijin and BioVaram will explore:

- Regulatory approval and commercialization of **SYNFOLIUM[®]**, a cardiovascular repair patch by [Teijin Medical Technologies Co., Ltd.](#), in India.
- Opportunities for expanding use of [Japan Tissue Engineering Co., Ltd.](#)'s regenerative medicine products in India. Japan Tissue Engineering (J-TEC) is part of the Teijin Group.
- Development and commercialization in Japan of BioVaram technologies, including exosome-based diagnostics and therapeutics, Extracellular Matrix mimics, and bio-derived materials such as Type I atelocollagen.



SYNFORIUM[®]



BioVaram Products

Takayuki Nakano, Ph.D., Mission Executive and General Manager, Regenerative Medicine & Implantable Medical Device Division of Teijin Limited., said *“The partnership with UR Advanced Therapeutics marks a highly significant step toward Teijin’s global expansion in the fields of regenerative medicine and implantable medical devices. By combining the exceptional technological capabilities and extensive expertise of both companies across the distinct markets of Japan and India, we are confident in our ability to deliver innovative therapies that address unmet medical needs in both countries.”*

Jaganmohan Reddy, Founder and CEO of UR Advanced Therapeutics, remarked, *“This MoU with Teijin Limited marks the beginning of a journey to bring India’s next-generation biotech innovations onto the global stage. It reinforces BioVaram’s vision to build transformative biotech innovations in India together with global partners. This partnership strengthens our capabilities in research, innovation, and scalable manufacturing of advanced tissue engineering products, while enabling Teijin to take BioVaram’s products to global markets. Together, we are shaping a future where biotechnology is transformative, sustainable, and deeply humane”.*”

Teijin established its Regenerative Medicine and Implantable Medical Devices division in 2022 by, integrating Teijin Medical Technologies, which manufactures bioabsorbable implantable devices; J-TEC, a pioneer in regenerative medicine; and [Teijin Regenex Co., Ltd.](#), a dedicated contract development and manufacturing organization (CDMO) for regenerative therapies. The group continues to grow with a mission to provide treatments that restore lost tissue and functions for patients.

Headquartered in Hyderabad, India, BioVaram is a rapidly growing biotechnology company recognized for its innovative regenerative medicine solutions. BioVaram offers AI-designed peptides, exosomes for therapeutic and diagnostic use, and bio-derived materials. The company has earned multiple awards, including being named a “Top 5 Startup” at BioAsia 2024.

Moving forward, the two companies will assess business feasibility, regulatory pathways, technical integration, and market needs to advance these initiatives. They will also collaborate on product development and manufacturing in cell and gene therapy, and pursue plans for introducing *SYNFOLIUM*® in India. By sharing market insights and regulatory information, Teijin and BioVaram aim to build a robust partnership that accelerates innovation in both countries.

About the Teijin Group

Teijin (TSE: 3401) is a technology-driven global group with two core businesses: high-performance materials and healthcare solutions. Established in 1918 as Japan’s first rayon manufacturer, Teijin today comprises some 170 companies employing 20,000 people. Teijin is committed to its Purpose, “Pioneering solutions together for a healthy planet.” Teijin works together with employees and external partners to achieve its Long-Term Vision, “To be a company that supports the society of the future.” Teijin posted consolidated revenue of JPY 1,005.5 billion and total assets of JPY 1,061.3 billion in the fiscal year ending March 31, 2025.

Teijin Group remains committed to achieving its fiscal 2030 sales target of JPY 20 billion in regenerative medicine by actively capturing global demand, strengthening its business foundation through facility expansion and talent development, and pursuing strategic partnerships worldwide.

Press Contacts

Corporate Communication Department, Teijin Limited

pr@teijin.co.jp

About BioVaram

BioVaram, the brand name of the UR Advanced Therapeutics (est. 2020), is a tissue engineering and regenerative medicine company pioneering AI-enabled peptide design for biomimetic materials, stem cells, and exosomes. Initially bootstrapped, the company later secured support from the ASPIRE Seed Fund and the BIRAC BIG Grant, followed by investments from Bhavya Constructions, Dr. K. I. Varaprasad Reddy, Founder of Shantha Biotechnics and Mr. Manoj Namburu and Consortium.

With these strategic investments, BioVaram is rapidly growing and building a state-of-the-art facility for regenerative medicine, focused on advancing AI-driven biomaterials, exosome technologies, and next-generation therapeutic platforms. The company recently launched its first AI-designed peptide product for cell death detection and exosome identification and purification—marking a breakthrough in translating computational innovation into practical healthcare solutions.

Guided by the mentorship of Dr. K. I. Varaprasad Reddy, the architect of India's first recombinant vaccine, BioVaram is committed to transforming innovation into accessible therapies that strengthen India's legacy of equitable and affordable healthcare.

The company's pioneering work has been recognized with multiple honours, including winning the Maharathi Challenge 2025, being selected for Booth Visit by the Prime Minister of India, and recognition among the Top 5 Startups at BioAsia 2024. These achievements underscore BioVaram's leadership in biotech innovation, transnational research, and its mission to build a robust, future-ready organization that keeps people at the centre of every breakthrough.

Press Contacts

Akhila Kasireddy

Corporate Communication Department, BioVaram

communications@biovaram.com